This small cap biotech stock has major catalysts on the horizon

NYSE-traded tiny biotech firm has a revolutionary offering You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please [unsubscribe]( here. This message is from Smallcaps Daily. --------------------------------------------------------------- [This NYSE company’s technology could be as revolutionary for viruses as antibiotics have been for bacteria!]( The biotech space is often looked at closely to see which innovative companies could change the world with their offerings. One small cap firm may soon redefine how we fight viruses with game changing broad-spectrum antiviral nanomedicines. These drugs work safely and effectively even against variants. The company’s lead drug alone addresses a $1.8 to $8 billion market! This lead drug candidate is a novel broad-spectrum antiviral that is being studied for the treatment of RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections. The treatment was substantially superior to remdesivir in coronavirus infections and was found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche)! The drug, developed in response to the COVID-19 pandemic, demonstrated exceptional safety in clinical trials, even at the highest dose levels, with NO adverse events reported. The unique mechanism of action involves mimicking a cell membrane, encapsulating and blocking the virus. Beyond COVID-19, the drug also displayed promising results against respiratory syncytial virus (RSV), offering a potential solution for infants and seniors where existing treatments like ribavirin may be contraindicated due to side effects. There is no drug for the general treatment of RSV infection at present, enabling this tiny biotech firm’s NV-387 offering to be a candidate for this $1.8 Billion to $8 Billion annual market size as estimated by GrowthPlus Reports! The company plans to advance the drug into a Phase II clinical trial for treatment of RSV infection in adults as part of the regulatory process required for registration of the drug for the treatment of pediatric RSV infection. [See how the company’s potentially revolutionary antiviral drug could fight deadly viruses like RSV while creating shareholder value.]( Regards, Smallcaps Daily Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $3,500 and was received/will be received from Interactive Offers. This compensation should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Financial Markets Daily. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 10/10/24. [Behind the Markets]( Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Unsubscribe]( Today's Bonus Content: [7 High-Yield Dividend Stocks to Buy Now]( (By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time)